{"entity":{"id":"forty-seven","kind":"company","name":"Forty Seven","aka":["Forty Seven, Inc.","NASDAQ:FTSV"],"tldr":"Forty Seven developed magrolimab, an antibody that blocks CD47, a signal cancer cells use to stop immune cells from swallowing them. Gilead bought the company in 2020.","summary":"Forty Seven, Inc. (formerly Nasdaq: FTSV), of Menlo Park, California, was a clinical-stage immuno-oncology company working on technology licensed from Stanford University. Its lead programme, magrolimab, is a monoclonal antibody against CD47, a 'don't eat me' signal that cancer cells use to avoid being engulfed by macrophages; at the time of sale it was in clinical studies in myelodysplastic syndrome, acute myeloid leukaemia and diffuse large B-cell lymphoma. Gilead agreed on 2 March 2020 to buy Forty Seven for USD 95.50 per share in cash, valuing it at about USD 4.9 billion, and the merger was completed on 7 April 2020.","asOf":"2026-11-03","links":[{"label":"Gilead to acquire Forty Seven (8-K exhibit 99.1, 2 March 2020)","url":"https://www.sec.gov/Archives/edgar/data/1667633/000119312520057799/d890968dex991.htm"},{"label":"Form 8-K: completion of the merger (7 April 2020)","url":"https://www.sec.gov/Archives/edgar/data/1667633/000110465920043980/a20-14980_68k.htm"}],"tags":[],"related":[],"cancers":["mds","aml","dlbcl"],"sections":["immunotherapy"],"technologies":["monoclonal-antibody"],"targets":["cd47"],"drugs":["magrolimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Completion on 7 April 2020 is from Forty Seven's 8-K of that date. What later happened to magrolimab is on its own page; this record does not restate it. No website or founding year is recorded."],"hq":"Menlo Park, CA","country":"US","companyType":"biotech","stage":"acquired","investors":[],"funding":[{"round":"Acquisition","year":2020,"amountUsd":4900000000,"source":"https://www.sec.gov/Archives/edgar/data/1667633/000119312520057799/d890968dex991.htm","note":"Gilead's announcement of 2 March 2020, filed as exhibit 99.1 to Forty Seven's 8-K: USD 95.50 per share in cash, approximately USD 4.9 billion"}],"acquiredBy":"gilead"},"route":"/companies/forty-seven/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"target":[{"id":"cd47","kind":"target","name":"CD47","route":"/targets/cd47/"}],"drug":[{"id":"magrolimab","kind":"drug","name":"Magrolimab","route":"/drugs/magrolimab/"}],"company":[{"id":"gilead","kind":"company","name":"Gilead Sciences (incl. Kite)","route":"/companies/gilead/"}]}}